Solventum (NYSE: SOLV) saw multiple analyst rating and target changes. Wedbush initiated coverage with an “outperform” rating and $94 target (5/15/26). UBS downgraded to “neutral” with $50 target (5/14/26) and previously cut its target to $78 (5/6/26). Other firms adjusted targets and ratings on 5/6/26, including Stifel ($90, buy), KeyCorp ($93, overweight), Wells Fargo ($70, equal weight), and BTIG ($89, buy). Director Amy Mcbride Wendell bought 1,475 shares at $68.03 (3/10/26).
Solventum Corporation (NYSE: SOLV) shareholders have approved the election of four Class II directors, the executive compensation plan on an advisory basis, and the re-appointment of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2026. The decisions were made at the company's annual shareholder meeting on May 15, 2026, with all proposals receiving strong majority support. This information was reported in an 8-K filing to the SEC.
3M Company is undergoing a significant transformation following the Solventum spin-off in April 2024, which has led to a narrower focus on industrial and safety-related categories. The company is managing litigation settlements and has reset its dividend framework to align with smaller cash flows. For investors, the key focus is on how management handles the post-spin-off balance sheet, portfolio mix, and cash returns, given the ongoing legal liabilities and the need for consistent operational execution.
